First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of.
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance .
Emergent BioSolutions (NYSE:EBS – Get Free Report) and Avid Bioservices (NASDAQ:CDMO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership. Analyst Recommendations This is a summary of […]
Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $M and Adjusted EBITDA of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08,.
Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20MUpdates.